Skip to content
Peptide research

Eloralintide

Also known as LY3841136
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
Not FDA-approved

Eloralintide is an investigational long-acting amylin receptor agonist being studied for weight loss, alone and in combination with tirzepatide. The weight-loss effect is well supported, but preferential fat loss, GI tolerability, and GLP-1 synergy claims rest on weak evidence. Nausea affects up to two-thirds of patients at higher doses, and safety data run only to 48 weeks, with none in pregnancy or children. It is not FDA-approved.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Eloralintide (LY3841136) is a next-generation obesity treatment developed by Eli Lilly that works through a different mechanism than GLP-1 drugs like semaglutide. It mimics amylin, a natural hormone your pancreas releases alongside insulin after meals, which signals fullness to the brain, slows digestion, and suppresses glucagon (a blood-sugar-raising hormone). Made of 37 amino acids with structural modifications for stability, eloralintide is designed for once-weekly injection. In Phase 2 trials, it achieved up to 20% body weight reduction over 48 weeks. Phase 3 trials (the ENLIGHTEN program) are underway as of early 2026.

How it works in the body

An amylin receptor agonist that activates receptors in the brain's hindbrain appetite centers. It signals fullness after meals, slows gastric emptying, and reduces glucagon secretion. As a long-acting analog, it maintains steady appetite-suppressing effects between doses.

Research overview

Eloralintide represents a new class of selective amylin receptor agonists for obesity. Its key advantage over competing amylin-based drugs like cagrilintide is 12-fold greater selectivity for the amylin receptor over the calcitonin receptor, which translates to better-targeted weight loss effects. Preclinical data showed that 80-91% of weight lost with eloralintide came from fat mass (versus 62-71% with cagrilintide), and it caused significantly less taste aversion — a common side effect of amylin drugs. Engineering modifications give it a half-life of roughly 13-15 days, supporting once-weekly dosing. Phase 1 results (100 patients) showed up to 11.3% weight loss at just 12 weeks with minimal gastrointestinal side effects. Phase 2 (263 patients) showed dose-dependent weight reductions of 9-20% over 48 weeks. Lilly is conducting Phase 3 monotherapy trials. Combination Phase 2b results were announced in September 2026, with Phase 3 trials of the EloraTZP co-formulation planned by year-end.

Who researches Eloralintide?

Commonly researched by

  • People researching weight management options

    Studied for effects on body composition, appetite regulation, or metabolic rate.

  • People researching GI and digestive health

    Studied for gastrointestinal protection, gut lining repair, or digestive support.

Important considerations for

  • Those with Personal/family history of MTC

    Absolute

    Note: Eloralintide is an amylin agonist, not an incretin — carries thyroid C-cell tumor class concern.

  • Those with History of pancreatitis

    High

    Incretin class pancreatitis monitoring required.

  • Those who are pregnant or breastfeeding

    Absolute

    Investigational — no reproductive safety data.

Safety & interactions

Do not use if

  • Personal/family history of MTC

    Absolute

    No approved eloralintide contraindication list or boxed warning exists. Eloralintide is a selective amylin agonist; an established GLP-1 thyroid-tumor class warning should not be assigned to it. Trial eligibility must follow the relevant protocol.

  • History of pancreatitis

    High

    A history of pancreatitis was an exclusion criterion in the Phase 2 trial. This is a trial precaution, not an established incretin-class requirement for eloralintide.

General cautions

  • Pregnancy

    Absolute

    Investigational — no reproductive safety data.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(9)

Rated by level of concern

  • Nausea: dose-dependent, from 11% at the lowest to 64% at the highest Phase 2 dose, vs 14% placebo

    High

    Lancet 2025 Phase 2 (PMID 41207310; doi:10.1016/S0140-6736(25)02155-5; NCT06230523)

  • Fatigue: reported in 0-46% of participants across dose groups vs 12% placebo

    Moderate

    Lancet 2025 Phase 2 (PMID 41207310); Bhattachar et al., Diabetes Obes Metab 2026 (doi:10.1111/dom.70439)

  • Decreased appetite: 19% in Phase 1 MAD study

    Low

    Bhattachar et al., Diabetes Obes Metab 2026 (doi:10.1111/dom.70439)

  • Headache: 12% in Phase 1 MAD study

    Low

    Bhattachar et al., Diabetes Obes Metab 2026 (doi:10.1111/dom.70439)

  • GI effects: diarrhea (10%), vomiting (4%) in Phase 1

    Moderate

    Bhattachar et al., Diabetes Obes Metab 2026 (doi:10.1111/dom.70439); Lancet 2025 Phase 2 (PMID 41207310)

  • Long-term safety unknown — only 48-week data available from Phase 2

    High

    Lancet 2025 Phase 2 (PMID 41207310; NCT06230523)

  • Injection site reactions possible (subcutaneous administration)

    Low

    Molecular Metabolism 2025 (PMID 41109426); subcutaneous route per NCT06230523

  • Contraindication data not yet fully established (investigational drug)

    High

    No FDA label exists; program status per Lancet 2025 Phase 2 (PMID 41207310) and ClinicalTrials.gov

  • Not studied in pregnancy, lactation, or pediatric populations

    High

    Trial population per Lancet 2025 Phase 2 (PMID 41207310; NCT06230523)

Interaction summary(7)

Rated by direction with this peptide

  • Insulin (any regimen)

    CautionHigh

    No eloralintide-specific data exist - the Phase 2 RCT explicitly enrolled participants without type 2 diabetes. Severity is kept High on class precedent, not direct evidence: pramlintide, the only approved amylin analog, carries an FDA boxed warning for severe insulin-induced hypoglycaemia requiring an upfront insulin dose reduction, and eloralintide shares amylin-receptor pharmacology (glucagon suppression, slowed gastric emptying). Severe hypoglycaemia is a life-threatening outcome, which is why severity is not softened despite the evidence being extrapolated. A combination trial in participants with type 2 diabetes (NCT06603571) is ongoing and has not reported.

    FDA SYMLIN (pramlintide acetate) prescribing information, NDA 021332 (boxed warning); eloralintide mechanism per Molecular Metabolism 2025 (PMID 41109426); T2D exclusion per NCT06230523

  • Sulfonylureas and meglitinides

    CautionModerate

    Entirely class-extrapolated. Insulin secretagogues combined with amylin-mediated glucagon suppression, delayed gastric emptying and reduced caloric intake could produce hypoglycaemia, so background secretagogue doses would plausibly need pre-emptive reduction. No published eloralintide trial has enrolled patients on secretagogues.

    Class extrapolation from FDA SYMLIN label; eloralintide Phase 2 excluded type 2 diabetes (NCT06230523)

  • GLP-1 and dual GIP/GLP-1 receptor agonists (semaglutide, tirzepatide)

    CautionModerate

    Synergy is the development hypothesis, not a finding: Lilly combination trials with tirzepatide are registered (NCT06916065 in overweight/obesity; NCT06603571 with type 2 diabetes); combination Phase 2b results were announced in September 2026, with no published efficacy or tolerability readouts. Meanwhile, using both adds two sources of nausea, vomiting and delayed gastric emptying, so additive GI burden and volume depletion are the realistic near-term concern.

    ClinicalTrials.gov NCT06916065, NCT06603571; mechanism per Molecular Metabolism 2025 (PMID 41109426)

  • Oral drugs requiring rapid or predictable absorption (analgesics, oral contraceptives, levothyroxine, narrow-therapeutic-index agents)

    CautionModerate

    Amylin receptor agonism slows gastric emptying, which can delay or blunt peak absorption of co-administered oral drugs. The pramlintide label carries timing guidance for oral agents where rapid onset matters (take them before, or well after, the injection). No dedicated eloralintide drug-interaction study has been published, so this is mechanism-plus-class reasoning rather than measured data for this agent.

    FDA SYMLIN (pramlintide acetate) prescribing information, NDA 021332; mechanism per Molecular Metabolism 2025 (PMID 41109426)

  • Other agents that slow GI motility (opioids, anticholinergics, tricyclic antidepressants)

    CautionTheoretical

    Additive suppression of gastric and intestinal motility could compound nausea, vomiting or constipation and, in susceptible patients, produce gastroparesis-like symptoms. Plausible from mechanism and consistent with incretin-class labelling, but not demonstrated for eloralintide in any published trial.

    Mechanism-based extrapolation; no published eloralintide interaction data

  • Diuretics, ACE inhibitors, ARBs and other volume-sensitive antihypertensives

    CautionLow

    Where nausea, vomiting or diarrhoea are significant - nausea reached up to 64% at higher doses in the 48-week Phase 2 RCT - reduced fluid intake combined with ongoing diuresis or RAAS blockade raises the risk of dehydration and pre-renal acute kidney injury. This is a recognized practical issue with weight-loss agents that cause GI symptoms; it has not been reported as an observed signal in the eloralintide trials.

    Lancet 2025 Phase 2 AE profile (PMID 41207310); class-level renal-safety reasoning

  • Other amylin analogs (pramlintide, cagrilintide, petrelintide)

    CautionTheoretical

    Duplicative pharmacology at the same receptor family offers no expected additional benefit while compounding nausea, vomiting and appetite suppression. No such combination has been studied and there is no therapeutic rationale for co-administration.

    Mechanism-based; no amylin-plus-amylin combination trials identified on ClinicalTrials.gov

Known risks(9)

  • Nausea: dose-dependent, from 11% at the lowest to 64% at the highest Phase 2 dose, vs 14% placebo

  • Fatigue: reported in 0-46% of participants across dose groups vs 12% placebo

  • Decreased appetite: 19% in Phase 1 MAD study

  • Headache: 12% in Phase 1 MAD study

  • GI effects: diarrhea (10%), vomiting (4%) in Phase 1

  • Long-term safety unknown — only 48-week data available from Phase 2

  • Injection site reactions possible (subcutaneous administration)

  • Contraindication data not yet fully established (investigational drug)

  • Not studied in pregnancy, lactation, or pediatric populations

Drug interactions(4)

  • Pramlintide (Symlin)

    Both are amylin receptor agonists. Combining would potentiate nausea, vomiting, and excessive appetite suppression.

  • Insulin

    Amylin analogs potentiate insulin-mediated glucose lowering. Hypoglycemia risk if co-administered without dose adjustment.

  • GLP-1 receptor agonists (semaglutide, liraglutide)

    Combination with tirzepatide has been studied in Phase 2b; results were announced in September 2026. Additive GI side effects possible. Not recommended outside clinical trials.

  • Oral medications (general)

    Amylin analogs slow gastric emptying, potentially affecting absorption of co-administered oral drugs. Timing separation may be needed.

Research & benefits

Evidence base

Evidence Level
Phase 2 (Lancet RCT, n=263)
Total Studies
5
Human Studies
At least 411 participants across the three cited completed studies, including placebo groups.

Phase 1 (n=48 SAD, n=100 MAD) and Phase 2 (n=263, 48-week RCT published in The Lancet) demonstrate dose-dependent weight loss up to 20% with favorable tolerability. Phase 3 ENLIGHTEN program initiated late 2025 across 171 global sites.

Researched for(6)

Rated by confidence in the evidence

  • Significant dose-dependent weight loss

    High

    48-week Phase 2 RCT showed dose-dependent weight loss, up to about 20%.

    Lancet 2025 Phase 2 (PMID 41207310; doi:10.1016/S0140-6736(25)02155-5; NCT06230523); Phase 1, Molecular Metabolism 2025 (PMID 41109426)

  • Preferential fat mass reduction

    Low

    A human Phase 2 DXA substudy found that most lost mass was fat. It did not establish the 80–91% preclinical figure or superiority over other treatments.

    Molecular Metabolism 2025 (PMID 41109426), preclinical findings; Lancet 2025 (PMID 41207310), human DXA substudy.

  • Favorable GI tolerability

    Low

    Phase 1 data suggested mild GI effects, but Phase 2 nausea reached up to 64%.

    Bhattachar et al., Diabetes Obes Metab 2026 (doi:10.1111/dom.70439); Lancet 2025 Phase 2 (PMID 41207310)

  • Convenient once-weekly dosing

    High

    Once-weekly subcutaneous dosing was the regimen tested in trials, not yet approved.

    Lancet 2025 Phase 2 (PMID 41207310; NCT06230523); Bhattachar et al., Diabetes Obes Metab 2026 (doi:10.1111/dom.70439)

  • Novel mechanism complementary to GLP-1 agonists

    Low

    The mechanism differs from GLP-1 drugs. Lilly announced randomized Phase 2b combination results in September 2026; a peer-reviewed report was not verified.

    Molecular Metabolism 2025 (PMID 41109426); ClinicalTrials.gov NCT06916065, NCT06603571

  • Rapid onset of weight loss

    Medium

    Human trials show an early weight-loss signal, not compared head-to-head with other drugs.

    Molecular Metabolism 2025 (PMID 41109426); Lancet 2025 Phase 2 (PMID 41207310)

Benefits(6)

  • Significant dose-dependent weight loss

  • Preferential fat mass reduction

  • Favorable GI tolerability

  • Convenient once-weekly dosing

  • Novel mechanism complementary to GLP-1 agonists

  • Rapid onset of weight loss

Key studies(3)

  1. Billings LK et al.

    The Lancet

    2025

    Dose-dependent weight loss: 9% (1mg), 12% (3mg), 18% (6mg), 20% (9mg) vs 0.4% placebo. Nausea 11-64% dose-dependent.

  2. Briere DA et al.

    Molecular Metabolism

    2025

    12-fold AMY1R selectivity over CTR. Single 12mg dose: -4.4% weight at 4 weeks. 80-91% fat mass loss in preclinical models.

  3. Bhattachar S, Tham LS, Tidemann-Miller B, Ibriga H, Qu H, Briere DA, Haupt A, Mather KJ, Pratt E

    Diabetes, Obesity and Metabolism

    2026

    Weight loss 2.6-11.3% across dose groups at 12 weeks. Nausea only 8%, well tolerated. Dose-proportional PK confirmed.

Regulation & availability

Why researchers look at it

Phase 2 results in 263 patients showed up to 20% weight loss over 48 weeks. About 60–70% of lost mass was fat in the human Phase 2 DXA substudy; a body-composition advantage over other treatments was not established. Nausea occurred in 8% in the small Phase 1 study and in up to 64% in Phase 2; comparative tolerability versus GLP-1 drugs has not been established head-to-head. Eloralintide targets amylin receptors rather than the GLP-1 pathway, a different mechanism. Lilly is conducting Phase 3 monotherapy trials, with Phase 3 trials of the EloraTZP co-formulation with tirzepatide planned by year-end.

Estimated cost
Not yet available — Phase 2 completed
FDA status
Investigational — not yet approved. Phase 2 completed August 2025 with results published in The Lancet (December 2025). Phase 3 ENLIGHTEN program initiated late 2025. No NDA/BLA has been filed. Given standard development timelines, earliest potential FDA approval would be 2028-2029 if Phase 3 trials are successful.
WADA status
Prohibited at all times under WADA S0 because eloralintide is investigational and has no identified governmental approval for human therapeutic use. A substance need not be named individually for S0 to apply.
Prescribability
No — investigational. Currently in Phase 3 clinical trials (ENLIGHTEN program). Not yet FDA-approved or commercially available.
Availability
Not commercially available. Eloralintide is an investigational drug in Phase 3 clinical trials (ENLIGHTEN program) sponsored by Eli Lilly. Access is currently limited to clinical trial enrollment at 171 sites across 15 countries. ClinicalTrials.gov identifier: NCT07321886 (ENLIGHTEN-1).

International status

  • EU

    Not approved

  • US

    Not FDA-approved

  • Worldwide

    No regulatory approval in any jurisdiction

Regulatory timeline(9)

  1. 2022-03
    Phase 1 SAD study initiatedSingle ascending dose study in 48 healthy participants
  2. 2022-2024
    Phase 1 MAD study completedMultiple ascending dose in 100 participants; 2.6-11.3% weight loss at 12 weeks
  3. 2024
    Phase 2 initiated48-week RCT across 46 US sites, 263 participants
  4. 2025-08
    Phase 2 completedPrimary endpoint met: dose-dependent weight loss up to 20%
  5. 2025-11
    Phase 2 results presented at ObesityWeekData presented and simultaneously published in The Lancet
  6. 2026
    Phase 3 ENLIGHTEN program initiatedENLIGHTEN-1 (NCT07321886), a Phase 3 monotherapy trial in adults with obesity or overweight without type 2 diabetes, is enrolling.
  7. 2025-12
    ENLIGHTEN-2 initiatedEloralintide for weight reduction in obesity with type 2 diabetes (NCT07282600)
  8. 2026 (ongoing)
    Phase 3 enrollment and combination studiesENLIGHTEN-4 (osteoarthritis + obesity). Eloralintide + tirzepatide Phase 2 combinations underway.
  9. 2028-2029 (projected)
    Potential FDA approvalIf Phase 3 trials successful, NDA/BLA filing and approval projected for this window

Sources & FAQs

Research sources(5)

Frequently asked questions(5)

How is eloralintide administered?

Subcutaneous injection. Despite early descriptions as an 'oral amylin analog,' eloralintide is administered by injection, not orally. Its long half-life (12.9-15.3 days) supports infrequent dosing.

How does eloralintide differ from semaglutide/tirzepatide?

Eloralintide works through the amylin receptor (AMY1R), not GLP-1 or GIP receptors. This distinct mechanism targets different satiety pathways, potentially enabling combination therapy with GLP-1/GIP agonists for additive weight loss.

What weight loss can be expected?

Phase 2 showed 9-20% weight loss over 48 weeks depending on dose. The highest-dose groups achieved approximately 20% reduction, comparable to high-dose GLP-1 agonists.

What are the main side effects?

Nausea (11-64% dose-dependent), fatigue (0-46%), decreased appetite (19%), headache (12%). GI side effects were notably lower than GLP-1 agonists in Phase 1 (8% nausea) but increased at higher doses in Phase 2.

When will eloralintide be available?

Phase 3 trials (ENLIGHTEN-1, ENLIGHTEN-2, ENLIGHTEN-4) are enrolling as of early 2026. If successful, FDA approval could come in 2028-2029. Currently only available through clinical trial participation.